89bioの空売り状況は、投資家が89bioの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

89bio (NASDAQ:ETNB) 株価情報, 空売り情報

89bio

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

89bio Inc

Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) shares are trading higher Tuesday after the company reported better-than-expected financial results for the fourth quarter and issued strong guidance. Several analysts also lifted price targets <a href="https://www.benzinga.com/news/earnings/25/02/43449486/palantir-q4-earnings-revenue-beat-eps-beat-us-revenue-up-52-customer-count-up-43-strong-guidance-th">following the print</a>.
<ul>
<li>Q4 Revenue: $827.52 million, versus <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">estimates</a>&nbsp;of $775.91 million</li>
</ul>
<ul>
<li>Q4 EPS: 14 cents, versus estimates of 11 cents</li>
</ul>
Total revenue grew 36% year-over-year, driven by strong U.S. revenue growth of 52% year-over-year. U.S. Commercial revenue increased 64% year-over-year to $214 million and U.S. Government revenue was up 45% year-over-year to $343 million.
Palantir's customer count grew 43% year-over-year and 13% on a quarter-over-quarter basis. The company said it closed 129 deals worth over $1 million during the quarter and 58 deals worth at least $5 million.
Palantir generated $460 million in cash from operations and $517 million in adjusted free cash flow in the quarter.&nbsp;The company ended the quarter with $5.2 billion of cash, equivalents and short-term U.S. treasury securities.
"We are still in the earliest stages, the beginning of the first act, of a revolution that will play out over years and decades," Palantir CEO Alex Karp said in a letter to shareholders.&nbsp;
"This is not an incremental advance or marginal acceleration of our business. This is a new phase. And the momentum we are seeing across sectors, both commercial and government, is unlike anything that has come before."
See Also: <a href="https://www.benzinga.com/markets/equities/25/02/43454250/palantir-is-making-america-more-lethal-as-alex-karp-led-company-secures-1-8-billion-in-ai-contracts-us-commercial-customer-base-surges-73">Palantir Is &#8216;Making America More Lethal&#8217; As Alex Karp-Led Company Secures $1.8 Billion in AI Contracts — US Commercial Customer Base Surges 73%</a>
Outlook:&nbsp;Palantir expects first-quarter revenue to be in the range of $858 million to $862 million, versus estimates of $799.35 million. The company expects full-year 2025 revenue to be between $3.74 billion and $3.76 billion versus estimates of $3.52 billion.&nbsp;
Palantir also guided for positive GAAP operating income and net income in each quarter of 2025 and said it anticipates full-year adjusted free cash flow between $1.5 billion and $1.7 billion.
&#8220;The business we have built has now developed its own internal momentum and strength, its own interior life and forms of untamed organic growth, with the output that we are seeing far surpassing what we are investing,&#8221; Karp added.
Analyst Changes:
<ul>
<li>Jefferies analyst Brent Thill maintained an Underperform and raised the price target from&nbsp;$28&nbsp;to&nbsp;$60.</li>
</ul>
<ul>
<li>BofA Securities analyst Mariana Perez Mora maintained a Buy and raised the price target from&nbsp;$90&nbsp;to&nbsp;$125.</li>
</ul>
<ul>
<li>Morgan Stanley analyst Sanjit Singh upgraded Palantir from Underweight to Equal-Weight and raised the price target from&nbsp;$60&nbsp;to&nbsp;$95.</li>
</ul>
<ul>
<li>Mizuho analyst Matthew Broome maintained an Underperform and raised the price target from&nbsp;$44&nbsp;to&nbsp;$80.</li>
</ul>
<ul>
<li>Northland Capital Markets analyst Michael Latimore maintained a Market Perform and raised the price target from&nbsp;$38&nbsp;to&nbsp;$80.</li>
</ul>
<ul>
<li>Baird analyst William Power maintained a Neutral and raised the price target from&nbsp;$70&nbsp;to&nbsp;$100.</li>
</ul>
<ul>
<li>Cantor Fitzgerald analyst Thomas Blakey maintained a Neutral and raised the price target from&nbsp;$72&nbsp;to&nbsp;$98.</li>
</ul>
PLTR Price Action: <a href="https://www.benzinga.com/quote/PLTR" target="_blank" rel="noreferrer noopener">Palantir shares </a>were up 22.5% at $102.55 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Earnings

News

Price Target

Movers

PLTR

Palantir Stock Is Surging Tuesday: What's Going On?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Stephens &amp; Co. raised Tyson Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) price target from $60 to $63. Stephens &amp; Co. analyst Pooran Sharma maintained an Equal-Weight rating. Tyson shares closed at $57.74 on Monday. <a href="https://www.benzinga.com/quote/TSN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Cantor Fitzgerald raised the price target for Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) from $50 to $55. Cantor Fitzgerald analyst Olivia Brayer maintained a Neutral rating. Bristol-Myers Squibb shares closed at $59.95 on Monday. <a href="https://www.benzinga.com/quote/BMY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo raised Marriott International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) price target from $262 to $285. Wells Fargo analyst Daniel Politzer maintained an Equal-Weight rating. Marriott shares closed at $290.46 on Monday. <a href="https://www.benzinga.com/quote/MAR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Cantor Fitzgerald raised the price target for Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) from $72 to $98. Cantor Fitzgerald analyst Thomas Blakey maintained a Neutral rating. Palantir shares closed at $83.74 on Monday. <a href="https://www.benzinga.com/quote/PLTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler cut the price target for Steven Madden, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) from $45 to $40. Piper Sandler analyst Anna Andreeva maintained a Neutral rating. Steven Madden shares closed at $38.32 on Monday. <a href="https://www.benzinga.com/quote/SHOO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley cut L3Harris Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) price target from $260 to $250. Morgan Stanley analyst Kristine Liwag maintained an Equal-Weight rating. L3Harris shares settled at $212.78 on Monday. <a href="https://www.benzinga.com/quote/LHX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays raised Baker Hughes Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NYSE">BKR</a>) price target from $51 to $55. Barclays analyst David Anderson maintained an Overweight rating. Baker Hughes shares closed at $47.40 on Monday. <a href="https://www.benzinga.com/quote/BKR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) price target from $125 to $17. Baird analyst Andrew Wittmann maintained an Outperform rating. AECOM shares closed at $103.85 on Monday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt raised the price target for Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) from $280 to $285. Rosenblatt analyst Mike Genovese maintained a Buy rating. Fabrinet shares settled at $225.60 on Monday. <a href="https://www.benzinga.com/quote/FN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler cut McDonald&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) price target from $297 to $290. Piper Sandler analyst Aisling Grueninger maintained a Neutral rating. McDonald&#8217;s shares closed at $290.05 on Monday. <a href="https://www.benzinga.com/quote/MCD/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43432950/jim-cramer-appfolio-is-a-cheap-stock-dont-sell-this-tech-stock">Jim Cramer Says AppFolio Is A &#8216;Good One,&#8217; But Summit Therapeutics? &#8216;Can&#8217;t Go There&#8217;</a></li>
</ul>

Analyst Ratings

Trading Ideas

SHOO

McDonald's To $290? Here Are 10 Top Analyst Forecasts For Tuesday

<a href="https://www.cnbc.com/2025/02/04/fox-subscription-streaming-service.html" title="https://www.cnbc.com/2025/02/04/fox-subscription-streaming-service.html">https://www.cnbc.com/2025/02/04/fox-subscription-streaming-service.html</a>

FOXA

'Fox Reveals Plans To Launch Subscription Streaming Service This Year' - CNBC

Amphenol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) has outperformed the market over the past 5 years by 9.63% on an annualized basis producing an average annual return of 21.93%. Currently, Amphenol has a market capitalization of $83.03 billion. 
Buying $1000 In APH: If an investor had bought $1000 of APH stock 5 years ago, it would be worth $2,680.34 today based on a price of $68.87 for APH at the time of writing.
<h3>Amphenol's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738679410_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Infineon Technologies (OTC:<a class="ticker" href="https://www.benzinga.com/stock/IFNNY#OTC">IFNNY</a>) released its Q1 earnings on Tuesday, February 4, 2025 at 05:00 AM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Infineon Technologies beat estimated earnings by 30.0%, reporting an EPS of $0.352 versus an estimate of $0.27.
Revenue was down $330.60 million from the same period last year.
<h3>Earnings History Overview</h3>
In the previous quarter, the company beat on EPS by $0.09, resulting in a 5.0% drop change in the share price the following day.

To track all earnings releases for Infineon Technologies <a href="https://www.benzinga.com/quote/IFNNY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IFNNY

Infineon Technologies Earnings Review: Q1 Summary

Quantum BioPharma Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) shares are rising Tuesday after the company announced positive clinical trial results for its <a href="https://www.benzinga.com/pressreleases/25/02/g43458239/quantum-biopharma-announces-the-success-of-unbuzzd-clinical-trial">unbuzzd dietary supplement</a>.
What Happened: Quantum BioPharma announced that it completed a double-blind, randomized, placebo-controlled crossover design clinical trial of unbuzzd that was aimed at investigating its effects on alcohol intoxication and alcohol metabolism.
Results showed that unbuzzed accelerated the rate at which Blood Alcohol Concentration (BAC) was reduced in study subjects, reducing symptoms of intoxication and hangover.
The rate at which BAC was lowered on average was more than 40% faster within 30 minutes of consuming unbuzzed. All results in the study were considered statistically significant compared to placebo. 
&#8220;This clinical trial shows that unbuzzd is an important addition to the safe and responsible consumption of alcohol. Consumers now have the benefit of knowing that unbuzzd can reduce alcohol intoxication, speed the reduction of blood alcohol concentration, restore mental alertness and well-being, and help them avoid the worst symptoms of a hangover,&#8221; said Zeeshan Saeed, CEO of Quantum BioPharma.
Check This Out: <a href="https://www.benzinga.com/25/02/43461426/mercks-gardasil-vaccine-slowdown-in-china-bites-again-stock-falls-on-lower-than-expected-2025-outlook">Merck&#8217;s Gardasil Vaccine Slowdown In China Bites Again, Stock Falls On Weak 2025 Outlook</a>
Quantum BioPharma said the effects of unbuzzd occurred within 30 minutes after consumption of the dissolved powder. The company noted that unbuzzd was well-tolerated and safe, with no reported product-related adverse effects.
Quantum BioPharma is considered a low-float stock with just 1.83 million shares available for public trading, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.&nbsp;The company also had a market cap of approximately $6 million as of Monday's close.&nbsp;Low-float, micro-cap stocks can be extremely volatile, which may be contributing to some of Tuesday's surge.
QNTM Price Action: <a href="http://benzinga.com/quote/qntm">Quantum BioPharma shares</a> were up 79.6% at $5.71 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
This illustration was generated using artificial intelligence via Midjourney.

QNTM

Quantum BioPharma Stock Is Soaring Tuesday: What's Driving The Action?

Alcoholic beverage company Diageo Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEO#NYSE">DEO</a>) released first-half <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">FY25 earnings results</a> and suspended medium-term guidance.
The company reported net <a target="_blank" href="https://www.diageo.com/en/news-and-media/press-releases/2025/2025-interim-results-half-year-ended-31-december-2024" rel="noreferrer noopener">sales </a>of $10.9 billion for the half year ended December 2024, reflecting a slight decline of 0.6% primarily driven by unfavorable foreign exchange fluctuations.
Despite the decrease, organic net sales showed a positive growth of 1.0%, bolstered by favorable price/mix changes. However, volume experienced a slight dip of 0.2%.
The company&#8217;s operating profit also decreased by 4.9%, with its operating profit margin shrinking by 132 basis points, impacted by currency movements and lower organic operating margins.
Despite this, Diageo managed to maintain or grow market share in 65% of total net sales value in measured markets, including the U.S.
Moët Hennessy&#8217;s significantly lower contribution and unfavorable currency exchange rates were the primary reasons behind a 9.6% drop in pre-exceptional earnings per share, which fell to 97.7 cents.
On the other hand, the company saw an increase in net cash flow, rising by $0.2 billion to reach $2.3 billion, with free cash flow rising to $1.7 billion, an increase of $0.1 billion compared to last year.
Given ongoing uncertainty in both the geopolitical and macroeconomic landscapes across key markets, Diageo has decided to withdraw its medium-term guidance.
Instead, the company has committed to providing more frequent near-term updates on its performance.
Also Read: <a target="_blank" href="https://in.benzinga.com/news/global/25/02/43442219/why-beer-tequila-avocados-cars-iphone-prices-could-rise-trumps-tariffs-on-canada-mexico-china-to-hurt-several-sectors" rel="noreferrer noopener">Why Beer, Tequila, Avocados, Cars, iPhone Prices Could Rise: Trump&#8217;s Tariffs On Canada, Mexico, China To Hurt Several Sectors</a>
&#8220;Diageo has anticipated and planned for a number of potential scenarios regarding tariffs in recent months. The confirmation at the weekend of the implementation of tariffs in the US, whilst anticipated, could very well impact this building momentum,&#8221; said CEO Debra Crew.
&#8220;It also adds further complexity in our ability to provide updated forward guidance given this is a new and dynamic situation. We are taking a number of actions to mitigate the impact and disruption to our business that tariffs may cause, and we will also continue to engage with the US administration on the broader impact that this will have on everyone supporting the US hospitality industry, including consumers, employees, distributors, restaurants, bars and other retail outlets.&#8221;
Diageo declared an interim dividend of 40.5 cents. The company&#8217;s leverage ratio stood at 3.1x net debt to EBITDA as of December 2024.
Price Action: DEO shares are trading lower by 0.06% at $116.86 in premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43432806/tyson-foods-posts-q1-earnings-protein-conscious-customers-drive-demand-ceo-calls-it-best-quarter-in-2-years" target="_blank" rel="noreferrer noopener">Tyson Foods Posts Q1 Earnings: Protein Conscious Customers Drive Demand</a></li>
</ul>
Image by pil76 via Shutterstock.

Equities

Guidance

General

Alcohol Giant Diageo Suspends Medium-Term Guidance As Trump's Tariff Looms

Dassault Systemes (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DASTY#OTC">DASTY</a>) reported its Q4 earnings results on Tuesday, February 4, 2025 at 06:30 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Dassault Systemes beat estimated earnings by 19.0%, reporting an EPS of $0.43 versus an estimate of $0.36.
Revenue was up $111.00 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.02 which was followed by a 3.0% drop in the share price the next day.
Here's a look at Dassault Systemes's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.30</td>
<td>0.32</td>
<td>0.32</td>
<td>0.40</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.32</td>
<td>0.32</td>
<td>0.33</td>
<td>0.39</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.60B</td>
<td>1.66B</td>
<td>1.67B</td>
<td>1.82B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.61B</td>
<td>1.61B</td>
<td>1.63B</td>
<td>1.77B</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Dassault Systemes management provided guidance for FY 2025, expecting earnings between $1.5 and $1.529 per share.
To track all earnings releases for Dassault Systemes <a href="https://www.benzinga.com/quote/DASTY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DASTY

Dassault Systemes Earnings Analysis: Q4 Recap

Parsons Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>) shares are trading relatively flat in the <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">premarket session on Tuesday.</a>
The firm announced the acquisition of TRS Group, an environmental solutions firm specializing in remediation technology, in an <a href="https://www.benzinga.com/pressreleases/25/02/g43458088/parsons-acquires-trs-group-inc" target="_blank" rel="noreferrer noopener">all-cash deal valued at $36 million.</a>
This deal is set to enhance Parsons&#8217; Federal Solutions and Critical Infrastructure segments, particularly in environmental remediation.
Founded in 2000, TRS Group addresses per- and polyfluoroalkyl substances (PFAS), along with other hazardous contaminants in soil, groundwater, and fire suppression systems.
TRS has completed over 160 thermal remediation projects. It aims to eliminate volatile organic compounds, including PFAS, energetics, and pesticides.
Also Read: <a href="https://www.benzinga.com/news/earnings/25/02/43457605/us-stocks-likely-to-open-lower-as-trumps-trade-war-continues-to-impact-the-market-volatility-is-the-toll-we-pay-to-invest-says-expert\" target="_blank" rel="noreferrer noopener">Stocks Likely To Open Lower As Trump&#8217;s Trade War Continues: &#8216;Volatility Is The Toll We Pay&#8217; Says Expert</a>
Its thermal remediation technology accelerates the breakdown of hazardous substances, offering an efficient and sustainable solution for environmental cleanup.
The acquisition significantly strengthens Parsons' position in the PFAS remediation market, an area of increasing importance due to growing state regulations and environmental concerns. TRS&#8217; license for the PerfluorAd technology, which helps remove PFAS from a range of systems, further adds to the value of this acquisition.
Parsons CEO Carey Smith expressed excitement about the synergies between both companies&#8217; cultures of innovation and commitment to improving environmental health.
&#8220;The acquisition of TRS Group significantly enhances Parsons&#8217; environmental remediation capabilities,&#8221; Smith said.
TRS President Brett Trowbridge highlighted the potential to create solutions that benefit communities and preserve natural resources as the two companies move forward together.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, PSN stock has gained over 18% in the past year. Investors can gain exposure to the stock via&nbsp;Professionally Managed Portfolios Otter Creek Focus Strategy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OCFS#NYSE">OCFS</a>).
Price Action: PSN shares are trading higher by 0.76% to $77.95 premarket at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/02/43456454/bill-gates-says-nvidias-jensen-huang-could-be-wrong-about-quantum-computing-qubt-rgti-ionq-react-in-tuesday-premarket" target="_blank" rel="noreferrer noopener">Bill Gates Says Nvidia's Jensen Huang ‘Could Be Wrong' About Quantum Computing: QUBT, RGTI, IONQ React In Tuesday Premarket</a></li>
</ul>
Image: Shutterstock

Markets

Professionally Managed Portfolios Otter Creek Focus Strategy ETF

OCFS

Parsons Acquires TRS Group In $36 Million Deal, Strengthening Its Position In Environmental Remediation Market

SNAX

Stryve Food Announces $9.4M Series A-1 Convertible Preferred Stock Issuance, Retires $8.7M Debt, Enhancing Financial Flexibility

Cummins Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) shares are trading higher premarket on Tuesday after the company reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43459106/cummins-reports-strong-fourth-quarter-and-full-year-2024-results-incurs-charges-associated-with-re" rel="noreferrer noopener">fourth-quarter&nbsp;2024&nbsp;results</a>.
Sales declined 1%&nbsp;year over year (Y/Y) to&nbsp;$8.45 billion, beating the consensus of&nbsp;$8.07 billion.
The Indiana-based company stated that sales in North America remained flat Y/Y and international revenues declined 3% Y/Y in the quarter.
Sales by segments:
<ul>
<li>Components&nbsp;$2.6&nbsp;billion&nbsp;(-17%&nbsp;Y/Y)</li>
<li>Engine&nbsp;$2.7&nbsp;billion&nbsp;(-2%&nbsp;Y/Y)</li>
<li>Distribution&nbsp;$3.1&nbsp;billion&nbsp;(+13%&nbsp;Y/Y)</li>
<li>Power Systems&nbsp;$1.7&nbsp;billion&nbsp;(+22%&nbsp;Y/Y)</li>
<li>Accelera&nbsp;$100&nbsp;million&nbsp;(+23%&nbsp;Y/Y).</li>
</ul>
EPS for the quarter stood at&nbsp;$3.02 compared to&nbsp;$4.59&nbsp;a year ago, missing <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">the consensus loss of&nbsp;$(10.01)</a>.
CMI reported an operating income of&nbsp;$732 million&nbsp;(vs. $1.2 billion a year ago quarter).
Cummins&#8217; operating cash for the quarter totaled&nbsp;$1.4 billion, compared to&nbsp;$1.46 billion&nbsp;a year ago.
At the end of December 2024, CMI held cash and equivalents of $1.67 billion.
EBITDA came in at&nbsp;$1.0 billion&nbsp;(12.1%&nbsp;of sales) vs. a loss of $878 million (-10.3%) last year.
"In the fourth quarter, we recorded charges related to the reorganization of our Accelera by Cummins segment. The charges were the result of a strategic review to streamline operations and focus investments, as the adoption of certain zero-emissions solutions has slowed in some regions around the world," said Jennifer Rumsey, chair and CEO of Cummins.
"In 2025, we anticipate that demand will be slightly weaker in the North America on-highway truck markets, particularly in the first half of the year, but offset by strength in other key markets. Despite a relatively flat revenue forecast and relative weakness in the key North America truck markets, we expect to improve profitability and cash flow."
2025&nbsp;Outlook:&nbsp;Cummins continues to expect revenue of down&nbsp;2%&nbsp;to up 3% and <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">EBITDA of&nbsp;16.2% and 17.2%</a>.
Investors can gain exposure to the stock via&nbsp;Honeytree U.S. Equity ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEEZ#NASDAQ">BEEZ</a>) and EA Series Trust TBG Dividend Focus ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBG#NYSE">TBG</a>).
Price Action:&nbsp;CMI shares are up 2.24% at $356.00 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43458771" target="_blank" rel="noreferrer noopener">McEwen Boosts Grey Fox Resources, Issues 2025 Guidance</a></li>
</ul>
Photo: Shutterstock

Large Cap

BEEZ

Cummins' Q4 Results Reflect International Weakness, Forecasts Modest Growth In 2025

Berry Global Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BERY#NYSE">BERY</a>) reported its Q1 earnings results on Tuesday, February 4, 2025 at 09:15 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Berry Global Gr beat estimated earnings by 10.0%, reporting an EPS of $1.09 versus an estimate of $0.99.
Revenue was down $468.00 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company beat on EPS by $0.02 in the previous quarter, leading to a 4.0% increase share price change the next day.
Here's a look at Berry Global Gr's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.25</td>
<td>2.05</td>
<td>1.91</td>
<td>1.29</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.27</td>
<td>2.18</td>
<td>1.95</td>
<td>1.22</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>3.13B</td>
<td>3.25B</td>
<td>3.16B</td>
<td>2.99B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>3.17B</td>
<td>3.16B</td>
<td>3.08B</td>
<td>2.85B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Berry Global Gr <a href="https://www.benzinga.com/quote/BERY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BERY

Berry Global Gr: Q1 Earnings Insights

On Tuesday,&nbsp;Pfizer Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) reported fourth-quarter adjusted EPS of 63 cents, compared to 10 cents a year ago, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/25/02/43455760/pfizer-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts" rel="noreferrer noopener">consensus of 47 cents</a>.
The U.S. drugmaker reported sales of $17.76 billion, up 22% year-over-year (up 21% operationally), beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus of $17.40 billion</a>.
The increase reflects a one-time, non-cash Paxlovid revenue reversal&nbsp;of $3.5 billion recorded in fourth-quarter 2023 and, to a lesser extent, growth contributions in fourth-quarter 2024 from the legacy Seagen portfolio, the Vyndaqel family, higher Paxlovid sales year-over-year, higher sales in several other products across all categories, and a favorable impact of foreign exchange.
Excluding contributions from Paxlovid and Comirnaty, fourth-quarter 2024 revenues <a target="_blank" href="https://s28.q4cdn.com/781576035/files/doc_financials/2024/q4/Q4-2024-Earnings-Charts-FINAL.pdf" rel="noreferrer noopener">totaled</a> $13.7 billion, an increase of $1.3 billion, or 11%, operationally compared with the prior-year quarter.
This was primarily driven by legacy Seagen, Vyndaqel family, Eliquis, Nurtec ODT/Vydura, and Xtandi, partially offset by lower revenues for Abrysvo, Xeljanz and Oncology biosimilars.
Read Next: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/01/43403416/is-big-pharma-about-to-win-goldman-sachs-weighs-in-on-340b-and-medicaid-shifts" rel="noreferrer noopener">Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts</a>
Fourth-quarter 2024 Comirnaty&nbsp;revenues of $3.83 billion decreased $2.0 billion, or 38%, operationally compared with the prior-year quarter, driven primarily by fewer COVID-19 vaccinations globally and lower contracted doses.
Fourth-quarter 2024 Paxlovid revenues of $727 million increased $3.9 billion operationally compared with $(3.1) billion of revenues recorded in the prior-year quarter, primarily driven by the transition to traditional commercial market sales in the U.S., including a one-time, non-cash revenue reversal&nbsp;of $3.5 billion recorded in fourth-quarter 2023.
Vyndaqel family drugs generated&nbsp;<a target="_blank" href="https://s28.q4cdn.com/781576035/files/doc_financials/2024/q4/Q4-2024-PFE-Earnings-Release-Final.pdf" rel="noreferrer noopener">sales</a> of $1.55 billion, up 60%. Eliquis, a blood thinner drug, generated sales of $1.83 billion, up 14%.
Global revenues of $915 million from legacy Seagen compared with $132 million in fourth-quarter 2023 following the completion of the acquisition in mid-December 2023.
Nurtec ODT/Vydura sales jumped 39% to $392 million. Prevnar family pneumococcal vaccine sales dipped 4% to $1.56 billion, and Abrysvo RSV vaccine sales slumped 62% to $198 million.
Guidance:&nbsp;Pfizer reaffirms 2025 revenues of $61 billion-$64 billion compared to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42530634/pfizer-does-not-anticipate-material-changes-to-us-vaccine-policy-from-the-incoming-administration-in-2025" rel="noreferrer noopener">consensus of $63.025 billion</a>.
The company anticipates adjusted EPS of $2.80-$3.00 compared to consensus of $2.94.
Price Action:&nbsp;At the last check on Tuesday, PFE stock was up 1.87% at $26.69 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43460556/tariff-trouble-rayonier-advanced-materials-braces-for-35m-monthly-loss-due-to-new-25-paperboard-tax" target="_blank" rel="noreferrer noopener">Tariff Trouble: Rayonier Advanced Materials Braces For $3.5M Monthly Loss Due To New 25% Paperboard Tax</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

Pfizer Q4 Earnings: Revenue And EPS Beat, Seagen And COVID-19 Products Show Strength, Issues Strong FY25 Outlook

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is trading around $99,200 on Tuesday, following China&#8217;s announcement of retaliatory tariffs on <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43454424/china-strikes-back-new-tariffs-up-to-15-on-certain-us-imports-in-retaliation-for-trumps-10-levy-on-chinese-goods">certain U.S. goods</a>.
What Happened: On Tuesday, China <a href="https://www.mof.gov.cn/zhengwuxinxi/caizhengxinwen/202502/t20250204_3955222.htm">announced </a>new tariffs on certain U.S. imports, marking a retaliatory response to recent U.S. trade measures. Beginning Feb. 10, China will impose:
<ul>
<li>A 15% tariff on coal and liquefied natural gas</li>
<li>A 10% tariff on crude oil, agricultural machinery and specific vehicle categories</li>
</ul>
Additionally, the Chinese Ministry of Commerce <a href="https://www.mofcom.gov.cn/zwgk/zcfb/art/2025/art_e623090907fc4e1092f0a4db72f57b95.html">revealed</a> new export restrictions on tungsten, tellurium, bismuth, molybdenum and indium, citing concerns over national security.
These critical materials play a key role in various industrial and technological applications.
China has strongly criticized the U.S. tariffs, stating: &#8220;The U.S.&#8217; unilateral imposition of tariffs severely violates the rules of the World Trade Organization.&#8221;
Why It Matters: Bitcoin's price fluctuations over the past two days reflect shifting investor sentiment tied to geopolitical events.
Geoffrey Kendrick, Head of Digital Assets Research at Standard Chartered, observed that recent developments have influenced market behavior.
&#8220;A huge turnaround in sentiment yesterday on the back of delayed Mexican and Canadian tariffs saw Bitcoin trade from a low of $91,300 to a high of $102,500,&#8221; he said in a note sent to Benzinga.
Although Bitcoin briefly surged past $100,000 on Monday following U.S. President Donald Trump's temporary pause on new tariffs for Mexico and Canada, its momentum was interrupted as trade tensions with China escalated.
Kendrick noted that Bitcoin's price action remains in a consolidation phase, with traders waiting for clearer signals from the U.S. bond market and broader economic indicators.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43460243/market-skeptical-of-doge-hype-questions-elon-musks-execution-bernstein-says">Market Skeptical Of DOGE Hype, Questions Elon Musk&#8217;s Execution, Bernstein Says</a>
What Experts Are Saying: The overall cryptocurrency market has gained 3.3% in the last 24 hours, rebounding from recent losses. However, sustained demand remains uncertain.
Alex Kuptsikevich, Chief Market Analyst at FxPro, pointed out that while Monday's rebound was strong, market enthusiasm appears to be fading:
&#8220;The violent recovery from Monday's kick-off crash has been losing traction for the past few hours. It seems that while the market has not gone into all-out sell-off mode, a reason for sustained buying is hard to find as threats of surprise tariffs persist.&#8221;
Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) is currently trading near $2,700, having dropped below its 200-day moving average, a key technical indicator. XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) is trading around $2.60, down from its Monday close of $2.78.
Kuptsikevich also noted that Ethereum often signals broader market trends, and its weakness suggests continued investor caution.
Despite recent swings, analysts emphasize Bitcoin's resilience in the face of macroeconomic challenges. 
Avinash Shekhar, co-founder and CEO of Pi42, highlighted how investor sentiment is shifting:
&#8220;Volatility and resilience are two sides of the same coin in the crypto market. Macroeconomic factors and investor confidence play a key role in shaping the market. The recent rebound in the crypto market highlights its growing correlation with broader economic trends,&#8221; he said.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43442344/bitcoin-ethereum-xrp-dip-leaves-crypto-industry-unfazed-were-going-a-marathon-expert-says">Bitcoin, Ethereum, XRP Dip Leaves Crypto Industry Unfazed: &#8216;We&#8217;re Going A Marathon,&#8217; Expert Says</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$XRP

Bitcoin Rally Stalls Around $99,000, Ethereum, XRP Struggle As China Imposes Retaliatory Tariffs

<a href="https://www.benzinga.com/personal-finance/24/09/40900871/donald-trump-says-inflation-is-the-highest-ever-but-experts-dispute-his-claims-heres-the-truth-a">President Donald Trump</a> has never been shy about his love for tariffs – he once called them "the most beautiful word in the dictionary." While experts debate their effectiveness, "Shark Tank" star Kevin O'Leary sees them as necessary tools for resetting trade relations, particularly with China.
"China&#8217;s a completely different issue compared to Canada or any other country. Since they joined the World Trade Organization, they've broken the rules with every country, including the U.S.," O'Leary said in a <a href="https://youtu.be/4pS2TdlwT7Q">recent interview</a> with Fox Business.
He didn't hold back on his frustrations, especially regarding his own business experiences. "I do business there, and my companies have been absolutely screwed. I&#8217;ve said it countless times. They don&#8217;t play fair, and there's no reciprocity in our trade relationship."
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>
Because of this, O'Leary believes in taking a hard line. He argued that the only way to pressure Chinese President Xi Jinping is to hit China's economy where it hurts – by targeting industries that employ large numbers of people.
"The only way to put [Xi] at risk is to say, ‘Look, if you want to mess with the biggest economy you trade with, we're going to force a lot of people in your cities – who make things like yoga mats or electronics – out of jobs.
They'll be rioting in the streets, they won't have food, and you'll be out of power.' That's the only way it's going to work – so you need very selective, high-impact tariffs, and you have to be hard core," he explained.
Trending: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
Trump has already proposed hitting Mexico and Canada with 25% tariffs on his first day in office and a 10% tariff on Chinese goods.
O'Leary believes this approach is necessary to level the playing field, saying, "[Xi] only understands the stick. That's it. Any sign of weakness, and he exploits it – he's been doing it for years. I'm hoping this administration finally fixes the problem. I've been hurt by <a href="https://www.benzinga.com/startups/24/09/41052368/chinas-alibaba-just-launched-a-wave-of-100-open-source-ai-models-including-a-text-to-video-tool-that">China</a>, and so have millions of other American businesses."
But tariffs aren't a simple fix. While they can protect U.S. industries by making imports more expensive, they also raise consumer prices.&nbsp;
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
A 2019 study from economists at the Federal Reserve Bank of New York, Princeton University and Columbia University found that "the tariff revenue the U.S. is now collecting is insufficient to compensate for the losses borne by the consumers of imports."&nbsp;
Tariffs can also trigger retaliation, leading to trade wars that disrupt supply chains. In an interview with Business Insider, Ian Sheldon, a professor at Ohio State University, pointed out that "we're already in a trade dispute with Mexico over genetically modified corn.&nbsp;
It seems counterproductive to potentially exacerbate trade relations with one of our largest trading partners."
Despite the uncertainty, many business leaders remain optimistic. During The New York Times DealBook Summit, Amazon founder Jeff Bezos said, &#8220;We are the luckiest country in the world. We have all these natural resources, including energy independence. We have the best risk capital system in the world, by far.&#8221;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100</a>.</li>
</ul>

Startups

Donald Trump's 25% Tariff Plan: 'Only Tough Measures Will Level the Playing Field' – Kevin O'Leary Explains the Strategy

Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) has outperformed the market over the past 5 years by 18.28% on an annualized basis producing an average annual return of 30.58%. Currently, Dell Technologies has a market capitalization of $70.05 billion. 
Buying $100 In DELL: If an investor had bought $100 of DELL stock 5 years ago, it would be worth $383.29 today based on a price of $100.40 for DELL at the time of writing.
<h3>Dell Technologies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738678508_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DELL

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

<ul>
<li>PLTR</li>
<li>NVDA</li>
<li>AMD</li>
<li>TSLA</li>
<li>GOOGL</li>
<li>WAR</li>
<li>GOOG</li>
<li>PYPL</li>
<li>SPOT</li>
<li>SMCI</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

GOOG

GOOGL

NVDA

PYPL

SMCI

SPOT

TSLA

Top 10 Trending Stocks On WallStreetBets As Of February 4, 2025 (Via Swaggy Stocks)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Joel Beatty initiated coverage on Catalyst Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with an Outperform rating and announced a price target of $28. Catalyst Pharmaceuticals shares closed at $22.62 on Monday. <a href="https://www.benzinga.com/quote/CPRX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst John Freeman initiated coverage on Expand Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Strong Buy rating and announced a price target of $135. Expand Energy shares closed at $102.87 on Monday. <a href="https://www.benzinga.com/quote/EXE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst John Kim initiated coverage on Terreno Realty Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRNO#NYSE">TRNO</a>) with a Market Perform rating and announced a price target of $71. Terreno Realty shares closed at $65.26 on Monday. <a href="https://www.benzinga.com/quote/TRNO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Andy Chen initiated coverage on Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with an Outperform rating and announced a price target of $49. Vera Therapeutics shares closed at $36.54 on Monday. <a href="https://www.benzinga.com/quote/VERA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Andy Chen initiated coverage on Oruka Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKA#NASDAQ">ORKA</a>) with an Outperform rating and announced a price target of $20. Oruka Therapeutics shares closed at $13.70 on Monday. <a href="https://www.benzinga.com/quote/ORKA/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock.</a></li>
</ul>
Considering buying EXE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-1024x593.png" alt="" class="wp-image-764898" style="width:551px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24.png 1110w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Initiation

Pre-Market Outlook

CPRX

ORKA

TRNO

VERA

This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Management

TSBX

Turnstone Says It Is Reducing Its Workforce While Also Implementing Further Cost-Containment And Cash Conservation Measures.

CMND

SPRC

SciSparc And Clearmind Announces Mexican Patent Application For MDMA And N-Acylethanolamines Therapy Combination

As previously reported, BofA upgraded Akero Therapeutics (AKRO) to Buy from Neutral with a price target of $63, up from $35. Akero's 96-week update...

Akero upgraded to Buy at BofA after 'transformative' liver data

BofA raised the firm's price target on 89bio (ETNB) to $34 from $30 and keeps a Buy rating on the shares. Akero Therapeutics' (AKRO) 96-week update...

89bio price target raised to $34 from $30 at BofA

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Akero raised to Buy at Bank of America after liver drug data

UBS raised the firm's price target on 89bio (ETNB) to $38 from $25 and keeps a Buy rating on the shares. Akero Therapeutics (AKRO) reported strong ...

89bio price target raised to $38 from $25 at UBS, says shares 'undervalued'

Wolfe Research initiated coverage of 89bio (ETNB) with an Outperform rating. Published first on TheFly – the ultimate source for real-time, market-...

89bio initiated with an Outperform at Wolfe Research

New insider activity at 89bio ( ($ETNB) ) has taken place on February 4, 2025. Ra Capital Management, LLC, previously a major shareholder, has made...

Major Investment Alert: 89bio Stock Sees Multi-Million Dollar Boost!

In a report released on February 2, Thomas Smith from Leerink Partners reiterated a Buy rating on 89bio (ETNB – Research Report), with a price targ...

89bio Stock Upgraded to Buy: Positive SYMMETRY Study Data Reinforces FGF21 Analog Potential

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 2/4/2025, According to Top Analysts

Ra Capital Management, a director and more than 10% owner of 89bio Inc. ($ETNB), bought common stock worth $49.99 million last week. This is the fi...

ETNB Insider Trade Alert! Majority Shareholder Sells $50M Worth of 89bio Stock

AKRO

ALLK

CVRX

ETNB

FLUX

LPTX

MSFT

NLSP

ONCO

QLGN

SLXN

TECX

TVGN

Press Releases

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024

Comments

89bio

空売り

89bio (NASDAQ:ETNB) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル